About Aditi Ganguly
Aditi is an experienced content developer and financial writer who is passionate about helping investors understand the do's and don'ts of investing. She has a keen interest in the stock market and has a fundamental approach when analyzing equities.
Aditi's fascination with the stock market began in college, where she majored in Economics, while researching The Great Recession for her thesis. After graduating, she began her career handling the content requirements for the mutual fund aggregator Groww. Since then she has become a financial journalist that focuses on writing articles that educate retail investors about the equity markets and the global economy.
Recent Articles By Aditi Ganguly
Is Huntsman a Good Value Stock to Own in 2021?
Huntsman Corporation (HUN) has managed to maintain its growth trajectory over the past year despite depressed demand. Even though its stock gained 35% in price over the past year, HUN is still trading at a discount compared to its peers. As the chemicals industry makes an anticipated V shaped recovery this year in tandem with the global economy, we think HUN should deliver significant returns.
Here's Why Growth Investors Should Buy Zedge Now
Zedge (ZDGE) is one of the world’s biggest content publishing platforms. It offers free personalization tools around the globe. Its unique portfolio of products and services has allowed it to generate healthy earnings over the past few years, which have been further bolstered by the effects of the COVID-19 pandemic. With the tech wave expected to continue for the foreseeable future, we expect ZDGE to continue on its growth streak.
Is Merck a Good Value Stock to Buy?
Merck (MRK) recently made headlines by withdrawing from the COVID-19 vaccine race. Its slow development of a vaccine, unimpressive results from its clinical trials and consequent withdrawal from the development race have driven the stock’s nearly 12% decline over the past year. However, the company still has a concrete drug pipeline dedicated to other critical ailments. But the question is will MRK’s earnings from its existing drug pipeline and new developments help it ride the biopharma rally? Read more to find out.
Should Value Investors Buy Tyson Foods Stock?
Renowned meat producer Tyson Foods (TSN) witnessed a decline in sales in early 2020 as COVID-19 shutdowns slammed its operations. But it recovered quickly as the global demand for quality meat rose. This has helped its stock gain in double digits over the past year. Because the global demand for meat is expected to rise in 2021 and because TSN is well-positioned to generate significant revenues, we think its current valuation is significantly discounted. Let’s take a closer look.
O'Reilly Automotive: Buy, Sell, or Hold?
O’Reilly Automotive (ORLY) has been benefiting from rising demand for auto spare parts and services because people's dependence on private modes of transportation has been on the rise amid the COVID-19 pandemic. However, an important question now is as the economy recovers in response to the ongoing vaccination drive, will ORLY be able to maintain its momentum? Read more to find out.
Will Under Armour Stock Continue to Rebound?
Under Armour’s (UAA) strong rebound from COVID-19 pandemic-led lows has been driven by the company’s global brand recognition. In the face of a changing sports apparel industry, the company is making structural changes to align its business model to profit from evolving consumer behavior. But will such changes allow UAA to retain its title as a leading sports apparel brand? Read more to find out.
Is Incyte a Good Biotech Stock to Add to Your Portfolio?
Though Incyte (INCY) is not directly involved in developing a vaccine for COVID-19, two drugs from its existing product pipeline have shown promise in the treatment of the disease. With rising cases of coronavirus worldwide, the company’s revenue and earnings are expected to rise. Currently trading at a discount to its peers, we think INCY should be a valuable addition to your portfolio. Let’s look closer at why.
Up More Than 400% in the Past Year, is Enphase Energy Still a Buy?
Enphase Energy’s (ENPH) stellar price performance and inclusion to the S&P 500 index has led to surging investor optimism regarding the stock. However, a closer look at the company’s fundamentals and valuation paints a more questionable picture. With governments worldwide remaining tightly focused on dealing with the ill effects of the COVID-19 pandemic, the question is will ENPH be able to maintain its rally? Read more to find out.
Steer Clear of These 2 Popular Electric Vehicle Stocks
Much effusive talk of an automotive industry transition from gasoline powered vehicles to electric ones has sent virtually all electric vehicle (EV) stocks on a giddy ascent. Investors are buying their shares based on broad market optimism rather than on specific company fundamentals. While NIO (NIO) and Workhorse Group (WKHS) have witnessed significant price gains over the past year, we believe they lack the fundamental strength to justify their inflated prices. Thus, these stocks are best avoided for now amid surging market volatility.